|
Apr 26
|
Nuwellis Announces Pricing of $2.7 Million Public Offering
|
|
Nov 28
|
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
|
|
Nov 14
|
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|